Online inquiry

IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14985MR)

This product GTTS-WQ14985MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Diseases or disorders including airway inflammation research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ14985MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ69MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ2480MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 181
GTTS-WQ178MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ5077MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAM-3001
GTTS-WQ13984MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ12729MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ2643MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 592
GTTS-WQ12504MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA NOE-102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW